A gene based model using nasopharyngeal carcinoma biomarkers AURKA and BUB1 accurately predicts survival and demonstrates ...

MRI showed more than 90% sensitivity in detecting nasopharyngeal carcinoma (NPC), surpassing endoscopy’s detection rate of 65.6% over a 5-year period. MRI particularly excelled in identifying ...

Researchers from the University of Hong Kong have discovered that the Epstein-Barr virus (EBV), a common human virus closely linked to nasopharyngeal carcinoma (NPC), can change the 3D structure of ...

In patients with nasopharyngeal carcinoma who received induction-concurrent (chemo)radiotherapy, persistent Epstein-Barr virus (EBV) DNA positivity or its resurgence during treatment was associated ...

Loqtorzi combined with chemotherapy nearly doubled median overall survival in nasopharyngeal carcinoma patients compared to chemotherapy alone, with a median survival of 64.8 months. The combination ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Individuals ...

Nasopharyngeal carcinoma (NPC), a malignancy that develops in the upper section of the throat behind the nose, occurs in fewer than one person out of 100,000 worldwide each year. Locally advanced ...

Penpulimab-kcqx is approved for first-line treatment of recurrent or metastatic non-keratinizing NPC in combination with cisplatin or carboplatin and gemcitabine. As a single agent, penpulimab-kcqx is ...